Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03863184
Title Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

mantle cell lymphoma

Therapies

Acalabrutinib + Lenalidomide + Rituximab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.